King buys Elan's primary care pharma unit
In support of its efforts to divest its non-core businesses, Elan Corp. sold to King Pharmaceuticals (acquires and sells branded pharmaceuticals) its US primary care pharmaceuticals unit for €786mm ($850mm) in cash.
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com